P.05 Incidence of osteonecrosis of the jaw in patients both treated with bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors

By: T. Van Cann , T. Loyson , C. Politis , P. Debruyne MD, PhD, B. Beuselinck MD, PhD

To read the full artice you have the following options:

Click here to log in. Register for a free subscription*

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €2.42

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)